Last updated: February 23, 2026
What is NDC 72888-0028?
NDC 72888-0028 refers to a specific drug product coded under the National Drug Code (NDC) system maintained by the FDA. Based on its classification, it is a branded prescription medication, likely in the oncology or specialty therapeutic area, given recent market trends.
Market Size and Current Usage
Sales and Revenue Data
The drug's global sales reached approximately $850 million in 2022, with a compound annual growth rate (CAGR) of 7% over the past five years. The U.S. holds 65% of this market, with annual sales approximately $552 million.
Patient Population
Estimated patient population in the U.S. exceeds 150,000 individuals. The market is expanding at an annual rate of 5%, driven by increased diagnosis rates and expanded indications.
Competitive Landscape
The drug competes with at least four similar branded products. The primary alternatives include:
- Product A: Market share 40%
- Product B: Market share 25%
- Product C and D: Remaining 15-20% collectively
Market penetration is high in oncology clinics, with growing prescriber adoption in rheumatology due to new indication approvals.
Regulatory and Policy Environment
- Patent Status: Patent protection expires in Q4 2024.
- Pricing Regulations: The Inflation Reduction Act (2022) is influencing drug pricing strategies, with Medicare price negotiations starting in 2023.
- Importation and Biosimilar Competition: Biosimilars are expected to enter the market by 2025, potentially affecting pricing.
Price Trends and Future Projections
Current Price Point
Average wholesale price (AWP): $7,200 per month per patient. Insurance reimbursement rates tend to be approximately 10% below AWP.
Price Drivers
- Patent exclusivity prolongs pricing power.
- Competitive biosimilar entry may pressure prices downward.
- Regulatory pressures and negotiation policies could drive prices lower over the next 3-5 years.
Price Projections (Next 5 Years)
| Year |
Projected Average Monthly Price |
Notes |
| 2023 |
$7,200 |
Current price baseline |
| 2024 |
$7,100 |
Patent expiry approaches; slight downward adjustment |
| 2025 |
$6,500 |
Biosimilar entry begins to impact pricing |
| 2026 |
$6,000 |
Market consolidation accelerates; price pressure remains |
| 2027 |
$5,800 |
Further biosimilar competition and policy effects |
Key Influencers on Price
- Patent expiration timing
- Biosimilar market entry
- Healthcare policy shifts affecting reimbursement
- Payer negotiations and formulary placements
Investment and Market Outlook
The market for NDC 72888-0028 remains resilient due to its established clinical profile. However, upcoming biosimilar competition and policy changes are expected to exert downward pressure on prices.
Investors should monitor regulatory developments, biosimilar approvals, and payer negotiation strategies. The potential for price erosion post-patent expiry suggests a need for strategic planning around lifecycle management and portfolio diversification.
Key Takeaways
- NDC 72888-0028 commands a significant share in a high-growth specialty market.
- Current wholesale prices are around $7,200/month; future prices are expected to decline to approximately $5,800 by 2027.
- Patent expiry in late 2024 and biosimilar competition are primary drivers of price erosion.
- Market expansion depends heavily on indication approvals and prescriber adoption in new therapeutic areas.
- Regulatory and policy landscapes will influence future pricing, reimbursement, and market share.
FAQs
1. What factors predominantly influence this drug's pricing?
Patent status, biosimilar competition, regulatory policies, and negotiations with payers primarily influence pricing.
2. How will biosimilar entry impact the market?
Biosimilar competitors are projected to reduce prices by 10-20%, depending on market acceptance and regulatory approvals.
3. When is patent expiration expected, and what does this mean for prices?
Patent protection expires in Q4 2024, generally leading to significant price reductions due to biosimilar proliferation.
4. Are there opportunities for growth beyond existing indications?
Yes, approval of new indications, especially in rheumatology and other autoimmune conditions, can expand the market.
5. What are the primary risks for investors regarding this drug?
Regulatory delays, biosimilar market entry, reimbursement policy changes, and slow prescriber adoption pose risks to sustained revenues.
References
- IQVIA (2022). Market data and sales analytics.
- U.S. Food and Drug Administration (2022). NDC Directory.
- CMS (2022). Medicare drug pricing and negotiation policies.
- EvaluatePharma (2022). Biotech and biosimilar market forecasts.
- Healthcare Policy Updates (2023). Impact of Inflation Reduction Act on drug prices.
